ATR
AptarGroup, Inc.
Is ATR Halal?
Dispensing, drug-delivery and packaging-component manufacturing — generally permissible activity whose known current asset-based ratios pass, with activity classification incomplete.
What You Should Know
AptarGroup's March 31, 2026 Form 10-Q reports assets of $5,097.783 million, debt and lease liabilities of $1,220.503 million, cash of $222.529 million, short-term investments of $6.948 million, receivables of $833.268 million and quarterly revenue of $982.868 million. Debt/assets is 23.94%, liquidity/assets is 4.50%, receivables plus cash/assets is 20.71% and disclosed investment-income interest is 0.37% of revenue. No universal prohibited-revenue numerator is disclosed.
⚠️ Concerns
- •Known asset-based ratios pass, but no universal prohibited-revenue numerator is disclosed
- •Pharmaceutical, beauty, food, beverage and home-care end markets require qualitative review
- •Debt, operating leases and acquisition activity require continuing review
- •Disclosed investment-income interest is 0.37% of quarterly revenue; no fixed purification percentage asserted
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-15.
1,220.503 / 5,097.783
229.477 / 5,097.783
1,055.797 / 5,097.783
3.642 / 982.868
- Financial
- Pass
- Overall
- Incomplete
Debt/assets is 23.94%, liquidity/assets is 4.50%, receivables-plus-cash/assets is 20.71% and disclosed interest income is 0.37%; known financial ratios pass, but the activity numerator is incomplete.
- Financial
- Pass
- Overall
- Incomplete
Known asset-based ratios are below the examined MSCI limits; the business-activity numerator remains incomplete.
- Financial
- Pass
- Overall
- Incomplete
Known debt and liquidity ratios pass the examined Malaysia limits; this is not an official classification and prohibited activity is not separately quantified.
- Financial
- Not calculated
- Overall
- Incomplete
A licensed historical market-cap series is not stored; the total-assets ratios are shown separately.
Business-activity disclosure
AptarGroup manufactures dispensing, sealing, drug-delivery and packaging systems. The core activity is generally permissible, but the filing does not provide a universal prohibited-revenue numerator for all end markets and end-product uses.
Limitation: No universal prohibited-activity revenue numerator or scholar-specific purification percentage is disclosed; no end-product estimate is invented.
Purification
Aptar discloses $3.642 million of investment-income interest, but no scholar-specific purification percentage is asserted and the activity numerator remains incomplete.
Inputs, assumptions and primary sources
- Amounts are USD millions from AptarGroup's March 31, 2026 Form 10-Q.
- Debt combines $1,176.490 million of long-term obligations including current maturities and $44.013 million of operating-lease liabilities; capital leases are included in the long-term-obligations presentation.
- Cash and cash equivalents are $222.529 million and short-term investments are $6.948 million. Equity investments are excluded from interest-bearing securities.
- Accounts notes and loans receivable are $833.268 million and first-quarter revenue is $982.868 million.
- Aptar reports $3.642 million of investment-income interest for the quarter (0.37% of revenue). No universal prohibited-revenue numerator is disclosed.
- Pharma drug-delivery, beauty dispensing and closures are generally permissible component-manufacturing activities, while end-product categories remain qualitative context.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →